Identification of an aptamer targeting hnRNP A1 by tissue slide‐based SELEX

We report a new in situ tissue slide‐based SELEX strategy targeting neoplastic tissues from breast cancer patients. The methodology, using the molecular differences between clinical specimens, can evolve aptamers to all fractions of tissue. The aptamers may be used as new molecular probes for pathological diagnosis and tumour imaging, and also to reveal the molecular differences that are responsible for the diseases. The specific aptamers were enriched by unequal length strand PCR employing a structured (−) strand primer. After 12 rounds of selection, using the paraffin tissue sections from infiltrating ductal carcinomas as targets, and using the adjacent normal tissue from the same case as controls, one of the enriched ssDNA aptamers, BC15, was selected from a nucleic acid library and characterized as recognizing breast cancer cells either within the tissue sections or from the culture medium, but only weakly binding to adjacent normal cells or immortalized breast cell line MCF10A. The calculated equilibrium dissociation constants (Kd) of BC15 bound to MCF7 cells was 111.0 ± 36.9 nM. Through streptavidin magnetic beads mediated affinity purification assay followed by mass spectrometry identification and western blot confirmation, the target of BC15 was characterized to be hnRNP A1, which was further verified to be specifically and highly expressed in cancerous tissues of breast by hnRNP A1 antibody immunostaining as well as western blot. BC15 aptamer was also used to probe cancer cells in tissues from other pathological types of breast cancers including lobular carcinoma, ductal carcinoma complicated with lobular carcinoma, comedo carcinoma, and lymph node metastasis of breast ductal carcinoma origin or breast lobular carcinoma origin. Therefore, tissue slide‐based SELEX holds promise in identifying tumour markers and developing specific molecular probes for cancer diagnosis. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  Joshua E. Smith,et al.  Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. , 2007, Analytical chemistry.

[2]  S. Dupuis,et al.  Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase , 1998, Nature Genetics.

[3]  Weihong Tan,et al.  Identification of liver cancer-specific aptamers using whole live cells. , 2008, Analytical chemistry.

[4]  A. Krainer,et al.  hnRNP A1 associates with telomere ends and stimulates telomerase activity. , 2006, RNA.

[5]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[6]  B. Chabot,et al.  Targeting heterogeneous nuclear ribonucleoparticule A1 and A2 proteins by RNA interference promotes cell death in transformed but not in normal mouse cell lines. , 2004, Molecular cancer therapeutics.

[7]  Ariel D. Anbar,et al.  Aptamers Evolved from Cultured Cancer Cells Reveal Molecular Differences of Cancer Cells in Patient Samples , 2007 .

[8]  J. M. Healy,et al.  Complex Target SELEX , 2008 .

[9]  L. Dwyer-Nield,et al.  Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre‐mRNA processing , 2004, Molecular carcinogenesis.

[10]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[11]  Weihong Tan,et al.  Molecular Recognition of Small‐Cell Lung Cancer Cells Using Aptamers , 2008, ChemMedChem.

[12]  Graeme I Murray,et al.  The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. , 2006, Biochimica et biophysica acta.

[13]  Naoto Tsuchiya,et al.  Up-regulation of hnRNP A1 gene in sporadic human colorectal cancers. , 2005, International journal of oncology.

[14]  A. Bergamaschi,et al.  hnRNP A1 Nucleocytoplasmic Shuttling Activity Is Required for Normal Myelopoiesis and BCR/ABL Leukemogenesis , 2002, Molecular and Cellular Biology.

[15]  SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT : TISSUE , .

[16]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[17]  Johanne Toutant,et al.  Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. , 2003, Cancer research.

[18]  J. Shay,et al.  A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation , 2002, Oncogene.

[19]  M. Olive,et al.  hnRNP A1 Recruited to an Exon In Vivo Can Function as an Exon Splicing Silencer , 1999, Molecular and Cellular Biology.

[20]  S. Dupuis,et al.  Heterogeneous Nuclear Ribonucleoprotein A1 and UP1 Protect Mammalian Telomeric Repeats and Modulate Telomere Replication in Vitro * , 2000, The Journal of Biological Chemistry.

[21]  Weihong Tan,et al.  Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. , 2006, Analytical chemistry.

[22]  Sergey N Krylov,et al.  Aptamer-facilitated biomarker discovery (AptaBiD). , 2008, Journal of the American Chemical Society.

[23]  B. Chabot,et al.  hnRNP A1 may interact simultaneously with telomeric DNA and the human telomerase RNA in vitro. , 2001, Nucleic acids research.

[24]  S. Vicent,et al.  Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. , 2003, Lung cancer.

[25]  B. Shen,et al.  Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. , 2003, Journal of biotechnology.